Abstract: It has been reported that statins increase osteogenic effects by inhibiting the cholesterol synthesis pathway. However, statins are unsuitable for local administration by themselves due to their rapid release in vivo. In order to develop the optimal concentration of fluvastatin-gelatin complexes for use as new osteogenic drugs, the purpose of this study was to investigate the coupled state of fluvastatin with gelatin in vitro. The coupling capacity of fluvastatin with gelatin was determined by measuring the remnant fraction of fluvastatin by ultrafiltration. Fluvastatin was dissolved at various concentrations (100, 200, 300, 400 and 500 M) into a 3-mg/ml gelatin solution. The complexes (500 µl) of fluvastatin solution and gelatin solution were filtered using a centrifugal ultrafilter at 15000 g in a swing-bucket rotor. The complexes were divided into an ultrafiltrated fraction containing fluvastatins freely released from the complex and a remnant fraction containing fluvastatin coupled with gelatin. The absorbance of the fluvastatin in the ultrafiltrated fraction was measured at 303 nm with an ultraviolet-visible transmission spectrophotometer. The fluvastatin-coupling capacity was then calculated based on a standard curve representing absorbance value vs. fluvastatin concentration. In addition, the osteogenic activity of fluvastatin coupled with gelatin was measured through the HMG-CoA reductase inhibitory activity in the cholesterol synthesis pathway. The results showed that a molecule of gelatin has coupling ability for a specific amount of fluvastatin (291 M fluvastatin/ 3 mg gelatin). The fluvastatin-gelatin complex had the same osteogenic activity as separately used fluvastatin through the inhibition of HMG-CoA reductase.
Introduction
Statins are widely used to lower cholesterol levels, which is an important role in the treatment of hyperlipidemia and arteriosclerosis. Recently, some papers have reported that statins have the effect of increasing the expression of bone morphogenetic protein-2 (BMP-2) through the inhibitory mechanism of HMGCoA reductase 1, 2) . Statins inhibit the synthesis of isoprenoid intermediates such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) by inhibiting the activity of HMG-CoA reductase 3) . As a result, statins increase the expression of BMP-2 mRNA through the inhibitory mechanism of the HMG-CoA and GGPP pathway 3) . In short, statins increase the osteogenic effect by inhibiting the initial part of the cholesterol synthesis pathway. However, statins are unsuitable for local administration by themselves due to their rapid release in vivo. Therefore, a drug delivery system (DDS) to control drug release is needed for developing a system of local administration. We have previously evaluated the osteogenic effects of a statin combined with gelatin hydrogel 4, 5) . In our studies, fluvastatin could be coupled with gelatin, and showed useful effects on osteogenic activity in rat calvaria during four weeks as a DDS, indicating that fluvastatin coupled with gelatin showed extended osteogenic effects in vivo. However, fluvastatin coupled with gelatin is still incomplete in establishing a DDS for osteogenic activity. Several studies have reported that statins have an optimal concentration for osteogenic effects in cell cultures 6) . Accordingly, in order to develop the optimal concentration of fluvastatin-gelatin complexes as new osteogenic drugs, the coupling capacity and activity of fluvastatin coupled with gelatin might provide important information.
The purpose of this study was to determine the fluvastatincoupling capacity of fluvastatin-gelatin complexes in vitro and to investigate the HMG-CoA reductase activity of fluvastatin-gelatin complexes through the cholesterol synthesis pathway.
Materials and Methods Materials Quantitative measurement of fluvastatin-coupling capacity of gelatin
In the present study, the fluvastatin-coupling capacity was determined by measuring the remnant fraction of fluvastatin by ultrafiltration. Vivaspin 500 with a polyethersulfone membrane (GE Healthcare, 100 kDa MWCO) was used for ultrafiltration. was also obtained. The fluvastatin-coupling capacity was calculated based on these absorbance curves.
Measurement of HMG-CoA reductase activity
In this study, the HMG-CoA Reductase Assay Kit (SigmaAldrich Chemie GmbH, Taufkirchen, Germany) was used for measuring the inhibitory activity of HMG-CoA reductase through the cholesterol synthesis pathway [7] [8] [9] [10] . 
Discussion
This study confirmed that the fluvastatin-coupling capacity was 291 µM fluvastatin to 3-mg/ml gelatin solution in the fluvastatin-gelatin complexes. This is thought to be due to the electrostatic coupling between negatively charged fluvastatin and positively charged alkaline gelatin. In addition, this result clearly demonstrated that a specific amount of fluvastatin had the ability to bind to gelatin molecules, enabling the local administration of fluvastatin in a drug delivery system and enhancing osteogenic activity.
Regarding the HMG-CoA reductase activity assay, fluvastatin coupled with gelatin inhibited HMG-CoA reductase activity for 20 minutes, the same as the fluvastatin solution. This result indicates that fluvastatin coupled with gelatin provides sufficient activity of HMG-CoA reductase inhibition same as fluvastatin alone. As previously explained, HMG-CoA reductase inhibition increased osteogenic effects through the cholesterol synthesis pathway, showed that the activity of HMG-CoA reductase inhibition affects osteogenic activity. In previous experiments, the results demonstrated that fluvastatin-gelatin complexes have the same osteogenic activity as does fluvastatin used separately. In addition, the fluvastatin-gelatin complexes showed extended osteogenic effects for four weeks 4, 5) . Considering our report, gelatin hydrogel can maintain the osteogenic effects of fluvastatin by providing the complex for four weeks in vivo, indicating that the fluvastatin-gelatin complex has the potential to heal bone wounds.
In conclusion, the present study demonstrates that fluvastatin can be combined with gelatin as a complex. The fluvastatin-gelatin complex provides the same osteogenic activity, as does fluvastatin used separately, by inhibiting HMG-CoA reductase.
